Ultime notizie per Biophytis (OTC:BPTSY) Azioni

Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.

Biophytis SA

Redburn Atlantic analyst Peter Low downgrades Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) from Neutral to Sell and lowers the price target from $156 to $124.

News

Downgrades

Price Target

Analyst Ratings

Redburn Atlantic Downgrades Chevron to Sell, Lowers Price Target to $124

<ul>
<li>The results of the in vitro release testing (IVRT) confirm that Ketamir-2 can be delivered reliably and consistently through a topical cream—a challenge that many water-soluble compounds fail to overcome when formulated in hydrophobic bases. This breakthrough provides MIRA with a new opportunity to pursue localized, non-opioid pain treatment options that may complement its oral Ketamir-2 formulation currently in Phase 1 trials.</li>
<li>MIRA is now initiating preclinical efficacy studies to assess whether the topical formulation can offer therapeutic effects in models of inflammatory and neuropathic pain. These studies are expected to provide data to guide potential clinical advancement.</li>
<li>MIRA is also evaluating whether the topical Ketamir-2 program may meet the criteria for Fast Track designation under the United States Food and Drug Administration ("FDA")'s expedited development program for serious conditions. If granted, Fast Track status could facilitate closer communication with the FDA and potentially accelerate the path to first-in-human studies.</li>
<li>MIRA's oral Ketamir-2 formulation is currently being evaluated in a Phase 1 clinical trial, with a Phase 2a trial in diabetic neuropathy expected to commence later this year.</li>
</ul>
&nbsp;

Biotech

Health Care

General

MIRA

MIRA Pharmaceuticals Announced A Key Development Milestone For Its Novel Topical Formulation Of Ketamir-2 Demonstrated Successful, Dose-proportional Drug Release In A Validated Laboratory Study-8K

PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW))) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3 at McCormick Place, Chicago, IL.
The details of the poster presentation sessions and publish-only abstract are listed below.
Abstract Title: Update on phase III pivotal trial of Bria-IMT + CPI vs physician's choice in advanced metastatic breast cancer (BRIA-ABC) Session Date and Time: 6/2/2025 9:00 AM-12:00 PM CDT Abstract Number for Publication: TPS1138 Poster Board Number: 108a Session Type and Title: Poster Session – Breast Cancer—Metastatic
Abstract Title: Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer Session Date and Time: 6/2/2025 9:00 AM-12:00 PM CDT Abstract Number for Publication: 1096 Poster Board Number: 75 Session Type and Title: Poster Session – Breast Cancer—Metastatic
Abstract Title: Trial in progress: A study of Bria-OTS cellular immunotherapy in metastatic recurrent breast cancer Session Date and Time: 6/2/2025 9:00 AM-12:00 PM&nbsp;CDT Abstract Number for Publication: TPS1136 Poster Board Number: 107a Session Type and Title: Poster Session – Breast Cancer—Metastatic
Publish-Only Abstract Title: Impact of HLA Matching on Clinical Outcomes in a Phase 2 Trial of Bria-IMT&#x2122; Plus Anti PD1 in Advanced Breast Cancer
Abstracts will be released at 5:00 PM (ET) on Thursday, May 22, 2025.

BCTX

TSX:BCT

Briacell Therapeutics Announces Three Clinical Data Poster Presentations And One Publish-Only Abstract At 2025 ASCO Annual Meeting At McCormick Place, Chicago

WIIM

PROG Holdings shares are trading lower after the company reported Q1 financial results and lowered FY25 revenue and EPS outlook. It also issued weaker-than-expected Q2 outlook.

SAP shares are trading higher after the company reported better-than-expected Q1 financial results.

Earnings

Earnings Beats

NextEra Energy Q1 Adj. EPS $0.99 Beats $0.97 Estimate

Stock Yards Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBT#NASDAQ">SYBT</a>) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $0.99 by 14.14 percent. This is a 28.41 percent increase over earnings of $0.88 per share from the same period last year. The company reported quarterly sales of $93.55 million which beat the analyst consensus estimate of $92.84 million by 0.76 percent. This is a 12.25 percent increase over sales of $83.34 million the same period last year.

SYBT

Stock Yards Bancorp Q1 EPS $1.13 Beats $0.99 Estimate, Sales $93.55M Beat $92.84M Estimate

2025 Outlook
In light of the deterioration in the macroeconomic environment since the Company issued its full-year outlook on February 19, 2025, the Company is updating its full year 2025 outlook for revenue and earnings as well as providing guidance for the second quarter of 2025. The updated outlook below assumes a difficult operating environment with soft demand for consumer durable goods, no material changes in the Company's current decisioning posture, an effective tax rate for Non-GAAP EPS of approximately 28%, and no impact from additional share repurchases. Additionally, the company has not assumed a recession which, among other factors, would likely be accompanied by a rise in the unemployment rate.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="6" rowspan="1">Revised 2025 Outlook</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="6" rowspan="1">Previous 2025 Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(In thousands, except per share amounts)</td>
<td colspan="3" rowspan="1">Low</td>
<td colspan="3" rowspan="1">High</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">Low</td>
<td colspan="3" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Total Revenues</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">2,425,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">2,500,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">2,515,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">2,590,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Net Earnings</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">109,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">125,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">115,500</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">133,500</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">245,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">265,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">260,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">280,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Diluted EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2.62</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">3.01</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2.82</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">3.22</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Diluted Non-GAAP EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2.90</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">3.30</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">3.10</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">3.50</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Progressive Leasing - Total Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,300,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,360,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,385,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,445,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Progressive Leasing - Earnings Before Taxes</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">168,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">185,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">181,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">195,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Progressive Leasing - Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">245,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">261,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">260,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">275,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Vive - Total Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">60,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">65,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">65,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">70,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Vive - Loss Before Taxes</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(5,000</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(3,500</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(5,500</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(2,500</td>
<td colspan="1" rowspan="1">)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Vive - Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(2,500</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(1,000</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(2,500</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">—</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other - Total Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">65,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">75,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">65,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">75,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other - Loss Before Taxes</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(9,000</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(7,500</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(9,000</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(6,000</td>
<td colspan="1" rowspan="1">)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other - Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,500</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">5,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,500</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">5,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="4" rowspan="1">
Three Months Ended
June 30, 2025 Outlook
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(In thousands, except per share amounts)</td>
<td colspan="2" rowspan="1">Low</td>
<td colspan="2" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Total Revenues</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">575,000</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">595,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Net Earnings</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">28,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">32,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">61,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">66,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Diluted EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.68</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.77</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Diluted Non-GAAP EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.75</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.85</td>
</tr>
</tbody>
</table>
</figure>

Guidance

PROG Holdings Q2 GAAP EPS Outlook $0.68-$0.77 Vs $0.84 Estimate

San Diego, California--(Newsfile Corp. - April 23, 2025) - Sonim Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>), a leading U.S. provider of rugged mobile solutions, today announced significant progress in the execution of its expansion strategy, underscoring the company's commitment to long term growth and operational excellence. The foundation laid through strategic investments in 2024 has positioned Sonim for success through the development and delivery of new products and product categories, new customer acquisitions, the retention of an existing customer base due to upgrades to the next generation portfolio, and market expansion across North America, Europe, South Africa, and Australia.
New products set to launch in North America, EMEA, and Australia
Sonim is set to launch three products as stocked offerings in the second quarter with Tier 1 carriers in North America. These include the company's flagship Sonim XP Pro next generation rugged 5G smartphone.
Three additional products are slated to launch in the second quarter with leading distribution partners and Tier 1 operators, including Deutsche Telekom in Germany, which currently stocks three Sonim SKUs. These new placements further strengthen Sonim's growing footprint in these key markets.
Purchase orders for second quarter launches
Validating market demand, purchase orders have already been placed for Sonim's upcoming product launches late in the second quarter. &nbsp;

SONM

Sonim Technologies Accelerates Expansion Strategy With Strong Momentum In Q2 2025; New Products Set To Launch In North America, EMEA, And Australia

PONY

Pony.ai Debuts 7th-Gen Autonomous System, Showcases Robotaxi Fleet At Shanghai Auto Show

PROG Holdings Q2 Outlook: Adj EPS $0.75-$0.85 Vs $0.90 Estimate; Sales $575.000M-$595.000M Vs $616.41M Estimate

JMP Securities analyst Silvan Tuerkcan initiates coverage on Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) with a Market Outperform rating and announces Price Target of $9.

Initiation

FHTX

JMP Securities Initiates Coverage On Foghorn Therapeutics with Market Outperform Rating, Announces Price Target of $9

PROG Holdings Lowers FY25 GAAP EPS Guidance From $2.82-$3.22 To $2.62-$3.01 Vs $3.12 Estimate

ROLLE, Switzerland and PLYMOUTH, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>), a leading differentiated automotive technology provider and Shaanxi Hande Axle Co., Ltd. (HanDe), a leading Chinese axle manufacturer for commercial vehicles, have signed a strategic agreement, including a series production award, to co-develop and manufacture advanced electric beam axle systems for medium and heavy-duty trucks. The signing took place today at the Shanghai Auto Show—China's flagship platform for mobility innovation—marking a significant milestone in the electrification of commercial transport.
Under the agreement, Garrett and HanDe will co-develop next-generation electric beam axle systems across truck weight classes, with production targeted for 2027. The solution will integrate Garrett's high-speed e-motor and inverter technology into HanDe's proven axle and transmission platforms—delivering industry-leading TCO, high performance, efficient packaging, and system scalability.
The strategic partnership includes a multi-year production award from major Chinese commercial vehicle manufacturers and will support both high-volume domestic output and international expansion. Initial manufacturing will take place in Xi'an and Wuhan, with test fleets set to begin field trials in 2026 as part of a broader global rollout strategy.
 &nbsp;

Garrett Motion Signs Strategic Agreement With Shaanxi Hande Axle To Co-Develop And Manufacture Advanced Electric Beam Axle Systems For Medium And Heavy-Duty Trucks

PROG Holdings Lowers FY25 Outlook: Adj EPS From $3.10-$3.50 To $2.90-$3.30 Vs $3.34 Estimate; Sales From $2.52B-$2.59B To $2.42B-$2.50B Vs $2.55B Estimate

Watsco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) reported quarterly earnings of $1.93 per share which missed the analyst consensus estimate of $2.25 by 14.22 percent. This is a 11.06 percent decrease over earnings of $2.17 per share from the same period last year. The company reported quarterly sales of $1.53 billion which missed the analyst consensus estimate of $1.65 billion by 7.46 percent. This is a 2.17 percent decrease over sales of $1.56 billion the same period last year.

Earnings Misses

Watsco Q1 EPS $1.93 Misses $2.25 Estimate, Sales $1.53B Miss $1.65B Estimate

JMP Securities analyst Silvan Tuerkcan initiates coverage on Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) with a Market Outperform rating and announces Price Target of $6.

NUVB

JMP Securities Initiates Coverage On Nuvation Bio with Market Outperform Rating, Announces Price Target of $6

Boeing shares are trading higher after the company reported better-than-expected Q1 financial results.

- Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment -
- Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of MDD patients -
- Patient dosing continues in APPROACH, Cybin's first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder ("MDD") -
- Second Phase 3 study, EMBRACE, is expected to begin mid-2025 -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54241503&amp;newsitemid=20250421948294&amp;lan=en-US&amp;anchor=Cybin&amp;index=1&amp;md5=fc680b58a980ffdba557ce8cc5154e2a">Cybin</a><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54241503&amp;newsitemid=20250421948294&amp;lan=en-US&amp;anchor=Inc&amp;index=2&amp;md5=68ac3d482ed3814303571360dea65d89"> Inc</a>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced additional strategic partnership agreements ("SPAs"), bringing the total to 18 clinical sites engaged to advance Cybin's multinational Phase 3 program evaluating CYB003 for the adjunctive treatment of MDD. The APPROACH study is expected to include approximately 45 clinical sites.

CYBN

Cybin Announces Additional Strategic Partnership Agreements To Support PARADIGM, Multinational Phase 3 Program Evaluating CYB003

OFG Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFG#NYSE">OFG</a>) reported quarterly earnings of $1.00 per share which beat the analyst consensus estimate of $0.97 by 3.09 percent. This is a 4.76 percent decrease over earnings of $1.05 per share from the same period last year. The company reported quarterly sales of $178.30 million which beat the analyst consensus estimate of $153.10 million by 16.46 percent. This is a 23.73 percent increase over sales of $144.10 million the same period last year.

Comments

Biophytis

Notizie

Ultime notizie per Biophytis (OTC:BPTSY) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO